The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.
End-Stage Kidney Disease, End-Stage Renal Disease
The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
-
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States, 02130-4817
Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota, United States, 55417-2309
VA NY Harbor Healthcare System, New York, NY, New York, New York, United States, 10010-5011
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
VA Office of Research and Development,
Areef Ishani, MD MS, STUDY_CHAIR, Minneapolis VA Health Care System, Minneapolis, MN
James S Kaufman, MD, STUDY_CHAIR, VA NY Harbor Healthcare System, New York, NY
2027-12-31